Early administration of Vitamin C in patients with sepsis or septic shock in emergency departments: A multicenter, double blinded, randomized controlled trial: The C-EASIE trial protocol.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
13
10
2021
accepted:
15
10
2021
entrez:
5
11
2021
pubmed:
6
11
2021
medline:
30
12
2021
Statut:
epublish
Résumé
Sepsis is a potentially life-threatening condition characterized by a deregulated body's response to infection causing injury to its own tissues and organs. Sepsis is the primary cause of death from infection. If not recognized and treated timely, it can evolve within minutes/hours to septic shock. Sepsis is associated with an acute deficiency of Vitamin C. Despite the proof-of-concept of the benefit of administering Vitamin C in patients with sepsis or septic shock, Vitamin C administration is not yet current practice. To investigate the potential benefit of early administration of high doses of Vitamin C in addition to standard of care in patients with sepsis or septic shock. This phase 3b multi-center trial is conducted in 8 hospitals throughout Belgium. In total 300 patients will be randomly assigned to one of two groups in a 1:1 allocation ratio. The intervention group will receive 1.5 g Vitamin C 4 times a day during 4 days, started within 6 hours after admission. The primary outcome is the average post-baseline patient SOFA score. This trial will determine whether the early administration of Vitamin C in patients with sepsis or septic shock can lead to a more rapid solution of shock and less deterioration from sepsis to septic shock, hereby reducing morbidity and mortality as well as the length of hospital stay in this patient population. The C-EASIE trial has been registered on the ClinicalTrials.gov website on 10 February 2021 with registration number NCT04747795. UZ Leuven (sponsor's reference S63213).
Sections du résumé
BACKGROUND
Sepsis is a potentially life-threatening condition characterized by a deregulated body's response to infection causing injury to its own tissues and organs. Sepsis is the primary cause of death from infection. If not recognized and treated timely, it can evolve within minutes/hours to septic shock. Sepsis is associated with an acute deficiency of Vitamin C. Despite the proof-of-concept of the benefit of administering Vitamin C in patients with sepsis or septic shock, Vitamin C administration is not yet current practice.
OBJECTIVE
To investigate the potential benefit of early administration of high doses of Vitamin C in addition to standard of care in patients with sepsis or septic shock.
METHODS
This phase 3b multi-center trial is conducted in 8 hospitals throughout Belgium. In total 300 patients will be randomly assigned to one of two groups in a 1:1 allocation ratio. The intervention group will receive 1.5 g Vitamin C 4 times a day during 4 days, started within 6 hours after admission. The primary outcome is the average post-baseline patient SOFA score.
CONCLUSION
This trial will determine whether the early administration of Vitamin C in patients with sepsis or septic shock can lead to a more rapid solution of shock and less deterioration from sepsis to septic shock, hereby reducing morbidity and mortality as well as the length of hospital stay in this patient population.
TRIAL REGISTRATION
The C-EASIE trial has been registered on the ClinicalTrials.gov website on 10 February 2021 with registration number NCT04747795.
TRIAL SPONSOR
UZ Leuven (sponsor's reference S63213).
Identifiants
pubmed: 34739527
doi: 10.1371/journal.pone.0259699
pii: PONE-D-21-32164
pmc: PMC8570477
doi:
Substances chimiques
Ascorbic Acid
PQ6CK8PD0R
Banques de données
ClinicalTrials.gov
['NCT04747795']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0259699Déclaration de conflit d'intérêts
NO authors have competing interests.
Références
Chest. 2020 Jul;158(1):164-173
pubmed: 32194058
Resuscitation. 2013 Apr;84(4):465-70
pubmed: 23295778
Crit Care. 2015 Nov 27;19:418
pubmed: 26612352
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
Eur J Emerg Med. 2021 Jun 1;28(3):189-195
pubmed: 33709993
Am J Respir Crit Care Med. 2017 Apr 1;195(7):906-911
pubmed: 27649072
J Res Pharm Pract. 2016 Apr-Jun;5(2):94-100
pubmed: 27162802
Acute Crit Care. 2021 Aug;36(3):185-200
pubmed: 34185986
Am J Clin Nutr. 1996 May;63(5):760-5
pubmed: 8615361
Chest. 2017 Jun;151(6):1229-1238
pubmed: 27940189
Curr Opin Crit Care. 2019 Aug;25(4):329-333
pubmed: 31107310
Biofactors. 2009 Jan-Feb;35(1):5-13
pubmed: 19319840
JAMA. 2019 Oct 1;322(13):1261-1270
pubmed: 31573637
Intensive Care Med. 2020 Nov;46(11):2015-2025
pubmed: 32780166
Crit Care Med. 2017 Mar;45(3):486-552
pubmed: 28098591
JAMA. 2021 Feb 23;325(8):742-750
pubmed: 33620405
BMC Med Res Methodol. 2011 Oct 26;11:144
pubmed: 22029846
Antioxid Redox Signal. 2013 Dec 10;19(17):2068-83
pubmed: 23581713
Pharmacol Ther. 2018 Sep;189:63-70
pubmed: 29684467
JPEN J Parenter Enteral Nutr. 2014 Sep;38(7):825-39
pubmed: 23917525
Crit Care. 2017 Dec 11;21(1):300
pubmed: 29228951
FASEB J. 2003 Oct;17(13):1928-30
pubmed: 12897061
Infect Dis (Lond). 2020 Apr;52(4):271-278
pubmed: 31990246
Stat Med. 2003 Dec 15;22(23):3571-81
pubmed: 14652861
JAMA. 2020 Aug 18;324(7):642-650
pubmed: 32809003
Crit Care. 2014 Aug 06;18(4):460
pubmed: 25185110
Chest. 2020 Jul;158(1):174-182
pubmed: 32243943
J Transl Med. 2014 Jan 31;12:32
pubmed: 24484547
JAMA. 2020 Feb 4;323(5):423-431
pubmed: 31950979